Sign in
4

Changes in Ownership

AGIOS PHARMACEUTICALS, INC. Filed Acc 0001439222-25-000063

Chief Executive Officer sold 18,700 shares at $33.54 ($627,198)

  • Chief Executive Officer acquired 38,277 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Goff Brian · Chief Executive Officer

Table I: Non-derivative

4 lines
Date Transaction Shares Price Value Owned after D/I
2025-06-24 Exercise or conversion : show line 1 in the form 10b5-1 +25,527 117,872 D
2025-06-24 Sale : show line 2 in the form 10b5-1 −12,471 $33.54 $418,277 105,401 D
2025-06-24 Exercise or conversion : show line 3 in the form 10b5-1 +12,750 118,151 D
2025-06-24 Sale : show line 4 in the form 10b5-1 −6,229 $33.54 $208,921 111,922 D
Open-market sales · 18,700 sh · avg $33.54 · $627,198

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2025-06-24 Exercise or conversion : show line 5 in the form 10b5-1 Performance share units −25,527 51,056 D
2025-06-24 Exercise or conversion : show line 6 in the form 10b5-1 Performance share units −12,750 12,750 D
Loading xslF345X05/wk-form4_1750972918.xml…